Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Published byAdrián Pereyra Modified over 5 years ago

Similar presentations

Presentation on theme: "Kamal Kant Singh Abbi, Junting Zheng, Sean M"— Presentation transcript:

1 Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma 
Kamal Kant Singh Abbi, Junting Zheng, Sean M. Devlin, Sergio Giralt, Heather Landau  Biology of Blood and Marrow Transplantation  Volume 21, Issue 3, Pages (March 2015) DOI: /j.bbmt Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 OS for MM patients undergoing a second ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 PFS for MM patients undergoing a second ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Kamal Kant Singh Abbi, Junting Zheng, Sean M"

Similar presentations

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.
A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.

A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation  Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.

Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation  Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.
Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous.

Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous.
Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.

Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Gunjan L. Shah,

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Gunjan L. Shah,
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.
Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation 

Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation 
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.

Similar presentations

Ads by Google